Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2′OMePS AON and ZM2 NP-AON complexes in mdx mice

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Bassi, Elena ^a   Falzarano, Sofia ^a   Fabris, Marina ^a   Gualandi, Francesca ^a   Merlini, Luciano ^b   Vattemi, Gaetano ^c   Perrone, Daniela ^a   Marchesi, Elena ^a   Sabatelli, Patrizia ^d   Sparnacci, Katia ^e   Laus, Michele ^e   Bonaldo, Paolo ^f   Rimessi, Paola ^a   Braghetta, Paola ^f   Ferlini, Alessandra ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Rizzoli Sicily IOR   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2' O PHOSPHOROTHIOATE ANTISENSE OLIGORIBONUCLEOTIDE; DYSTROPHIN; NANOPARTICLE; OLIGORIBONUCLEOTIDE; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; NANOCAPSULE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; TREATMENT OUTCOME; UPREGULATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALIA; MUS;

ANIMALS; DYSTROPHIN; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; NANOCAPSULES; OLIGONUCLEOTIDES, ANTISENSE; TREATMENT OUTCOME; UP-REGULATION;

EID: 84871822017     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/897076     Document Type: Article

References (40)

1. Aartsma-Rus A., Van Deutekom J. C. T., Fokkema I. F., Van Ommen G. J. B., Den Dunnen J. T., Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle and Nerve 2006 34 2 135 144 2-s2.0-33746766278 10.1002/mus.20586 (Pubitemid 44167796)
2. Aartsma-Rus A., Van Ommen G. J. B., Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007 13 10 1609 1624 2-s2.0-34748906143 10.1261/rna.653607 (Pubitemid 47481669)
3. Hoffman E. P., Skipping toward personalized molecular medicine. The New England Journal of Medicine 2007 357 26 2719 2722 2-s2.0-37549049805 10.1056/NEJMe0707795
4. Du L., Gatti R. A., Progress toward therapy with antisense-mediated splicing modulation. Current Opinion in Molecular Therapeutics 2009 11 116 123
5. van Deutekom J. C., Janson A. A., Ginjaar I. B., Frankhuizen W. S., Aartsma-Rus A., Bremmer-Bout M., Den Dunnen J. T., Koop K., Van Der Kooi A. J., Goemans N. M., De Kimpe S. J., Ekhart P. F., Venneker E. H., Platenburg G. J., Verschuuren J. J., Van Ommen G. J. B., Local dystrophin restoration with antisense oligonucleotide PRO051. The New England Journal of Medicine 2007 357 26 2677 2686 2-s2.0-37549034298 10.1056/NEJMoa073108
6. Kinali M., Arechavala-Gomeza V., Feng L., Cirak S., Hunt D., Adkin C., Guglieri M., Ashton E., Abbs S., Nihoyannopoulos P., Garralda M. E., Rutherford M., Mcculley C., Popplewell L., Graham I. R., Dickson G., Wood M. J., Wells D. J., Wilton S. D., Kole R., Straub V., Bushby K., Sewry C., Morgan J. E., Muntoni F., Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology 2009 8 10 918 928 2-s2.0-69949107887 10.1016/S1474-4422(09)70211-X
7. Goemans N. M., Tulinius M., van den Akker J. T., Burm B. E., Ekhart P. F., Heuvelmans N., Holling T., Janson A. A., Platenburg G. J., Sipkens J. A., Sitsen J. M. A., Aartsma-Rus A., Van Ommen G. J. B., Buyse G., Darin N., Verschuuren J. J., Campion G. V., Kimpe S. J. D., Van Deutekom J. C., Systemic administration of PRO051 in Duchenne's muscular dystrophy. The New England Journal of Medicine 2011 364 16 1513 1522 2-s2.0-79955158683 10.1056/NEJMoa1011367
8. Cirak S., Arechavala-Gomeza V., Guglieri M., Feng L., Torelli S., Anthony K., Abbs S., Garralda M. E., Bourke J., Wells D. J., Dickson G., Wood M. J., Wilton S. D., Straub V., Kole R., Shrewsbury S. B., Sewry C., Morgan J. E., Bushby K., Muntoni F., Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet 2011 378 9791 595 605 2-s2.0-79960533369 10.1016/S0140-6736(11)60756-3
9. Williams J. H., Schray R. C., Sirsi S. R., Lutz G. J., Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. BMC Biotechnology 2008 8, article 35 2-s2.0-42949126622 10.1186/1472-6750-8-35 (Pubitemid 351619156)
10. Kim Y., Tewari M., Pajerowski J. D., Cai S., Sen S., Williams J., Sirsi S., Lutz G., Discher D. E., Polymersome delivery of siRNA and antisense oligonucleotides. Journal of Controlled Release 2009 134 2 132 140 2-s2.0-60649114699 10.1016/j.jconrel.2008.10.020
11. Sirsi S. R., Schray R. C., Guan X., Lykens N. M., Williams J. H., Erney M. L., Lutz G. J., Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Human Gene Therapy 2008 19 8 795 806 2-s2.0-50649089185 10.1089/hum.2007.129
12. Tao W., Davide J. P., Cai M., Zhang G. J., South V. J., Matter A., Ng B., Zhang Y., Sepp-Lorenzino L., Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Molecular Therapy 2010 18 9 1657 1666 2-s2.0-77956265264 10.1038/mt.2010.147
13. Yang X. Z., Dou S., Sun T. M., Mao C. Q., Wang H. X., Wang J., Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. Journal of Controlled Release 2011 156 203 211
14. de Martimprey H., Bertrand J. R., Malvy C., Couvreur P., Vauthier C., New core-shell nanoparticules for the intravenous delivery of sirna to experimental thyroid papillary carcinoma. Pharmaceutical Research 2010 27 3 498 509 2-s2.0-77949270747 10.1007/s11095-009-0043-8
15. Bertholon I., Vauthier C., Labarre D., Complement activation by core-shell poly(isobutylcyanoacrylate)- polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharmaceutical Research 2006 23 6 1313 1323 2-s2.0-33745402302 10.1007/s11095-006-0069-0 (Pubitemid 43946153)
16. Davis M. E., Zuckerman J. E., Choi C. H. J., Seligson D., Tolcher A., Alabi C. A., Yen Y., Heidel J. D., Ribas A., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010 464 7291 1067 1070 2-s2.0-77951132901 10.1038/nature08956
17. Rimessi P., Sabatelli P., Fabris M., Braghetta P., Bassi E., Spitali P., Vattemi G., Tomelleri G., Mari L., Perrone D., Medici A., Neri M., Bovolenta M., Martoni E., Maraldi N. M., Gualandi F., Merlini L., Ballestri M., Tondelli L., Sparnacci K., Bonaldo P., Caputo A., Laus M., Ferlini A., Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Molecular Therapy 2009 17 5 820 827 2-s2.0-67349244344 10.1038/mt.2009.8
18. Ferlini A., Sabatelli P., Fabris M., Bassi E., Falzarano S., Vattemi G., Perrone D., Gualandi F., Maraldi N. M., Merlini L., Sparnacci K., Laus M., Caputo A., Bonaldo P., Braghetta P., Rimessi P., Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. Gene Therapy 2010 17 3 432 438 2-s2.0-77949423798 10.1038/gt.2009.145
19. Heemskerk H., de Winter C., Van Kuik P., Heuvelmans N., Sabatelli P., Rimessi P., Braghetta P., Van Ommen G. J. B., De Kimpe S., Ferlini A., Aartsma-Rus A., Van Deutekom J. C., Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Molecular Therapy 2010 18 6 1210 1217 2-s2.0-77953134497 10.1038/mt.2010.72
20. Ferlini A., Rimessi P., Exon skipping quantification by real-time PCR. Methods in Molecular Biology 2012 867 189 199
21. Spitali P., Rimessi P., Fabris M., Perrone D., Falzarano S., Bovolenta M., Trabanelli C., Mari L., Bassi E., Tuffery S., Gualandi F., Maraldi N. M., Sabatelli-Giraud P., Medici A., Merlini L., Ferlini A., Exon skipping-mediated dystrophin reading frame restoration for small mutations. Human Mutation 2009 30 11 1527 1534 2-s2.0-70350731131 10.1002/humu.21092
22. Sewry C. A., Immunocytochemical analysis of human muscular dystrophy. Microscopy Research and Technique 2000 48 3-4 142 154 2-s2.0-0033960712 (Pubitemid 30086188)
23. Kayali R., Bury F., Ballard M., Bertoni C., Site-directed gene repair of the dystrophin gene mediated by PNA-ssODNs. Human Molecular Genetics 2010 19 16 3266 3281 2-s2.0-77955025555 10.1093/hmg/ddq235
24. Fletcher S., Honeyman K., Fall A. M., Harding P. L., Johnsen R. D., Wilton S. D., Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligunucleotide. Journal of Gene Medicine 2006 8 2 207 216 2-s2.0-32844460899 10.1002/jgm.838 (Pubitemid 43250701)
25. Alter J., Lou F., Rabinowitz A., Yin H., Rosenfeld J., Wilton S. D., Partridge T. A., Qi L. L., Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Medicine 2006 12 2 175 177 2-s2.0-32244443828 10.1038/nm1345 (Pubitemid 43214742)
26. Wu B., Moulton H. M., Iversen P. L., Jiang J., Li J., Li J., Spurney C. F., Sali A., Guerron A. D., Nagaraju K., Doran T., Lu P., Xiao X., Qi L. L., Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proceedings of the National Academy of Sciences of the United States of America 2008 105 39 14814 14819 2-s2.0-54449095504 10.1073/pnas.0805676105
27. Jearawiriyapaisarn N., Moulton H. M., Sazani P., Kole R., Willis M. S., Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovascular Research 2010 85 3 444 453 2-s2.0-74249109987 10.1093/cvr/cvp335
28. Yin H., Saleh A. F., Betts C., Camelliti P., Seow Y., Ashraf S., Arzumanov A., Hammond S., Merritt T., Gait M. J., Wood M. J. A., Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Molecular Therapy 2011 19 7 1295 1303 2-s2.0-79959995255 10.1038/mt.2011.79
29. Heemskerk H. A., de Winter C. L., de Kimpe S. J., van Kuik-Romeijn P., Heuvelmans N., Platenburg G. J., van Ommen G. J. B., van Deutekom J. C. T., Aarstsma-Rus A., In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. Journal of Gene Medicine 2009 11 3 257 266 2-s2.0-65349121206 10.1002/jgm.1288
30. Qi L. L., Rabinowitz A., Yun C. C., Yokota T., Yin H., Alter J., Jadoon A., Bou-Gharios G., Partridge T., Systemic delivery of antisense oligoribonucleotide restorers dystrophin expression in body-wide skeletal muscles. Proceedings of the National Academy of Sciences of the United States of America 2005 102 1 198 203 2-s2.0-11844256373 10.1073/pnas.0406700102 (Pubitemid 40094452)
31. Wu B., Lu P., Benrashid E., Malik S., Ashar J., Doran T. J., Lu Q. L., Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Therapy 2010 17 1 132 140 2-s2.0-74349109205 10.1038/gt.2009.120
32. Fletcher S., Honeyman K., Fall A. M., Harding P. L., Johnsen R. D., Steinhaus J. P., Moulton H. M., Iversen P. L., Wilton S. D., Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Molecular Therapy 2007 15 9 1587 1592 2-s2.0-34547691961 10.1038/sj.mt.6300245 (Pubitemid 47289001)
33. Jearawiriyapaisarn N., Moulton H. M., Buckley B., Roberts J., Sazani P., Fucharoen S., Iversen P. L., Kole R., Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Molecular Therapy 2008 16 9 1624 1629 2-s2.0-50549093417 10.1038/mt.2008.120
34. Malerba A., Thorogood F. C., Dickson G., Graham I. R., Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Human Gene Therapy 2009 20 9 955 965 2-s2.0-67650391305
35. Moulton H. M., Moulton J. D., Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochimica et Biophysica Acta 2010 1798 12 2296 2303 2-s2.0-77958152873 10.1016/j.bbamem. 2010.02.012
36. Monteith D. K., Horner M. J., Gillett N. A., Butler M., Geary R., Burckin T., Ushiro-Watanabe T., Levin A. A., Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicologic Pathology 1999 27 3 307 317 2-s2.0-0033060190 (Pubitemid 29245041)
37. Ferdinandi E. S., Vassilakos A., Lee Y., Lightfoot J., Fitsialos D., Wright J. A., Young A. H., Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemotherapy and Pharmacology 2011 68 1 193 205 2-s2.0-79959624824 10.1007/s00280-010-1473-z
38. Wells D. J., Wells K. E., Asante E. A., Turner G., Sunada Y., Campbell K. P., Walsh F. S., Dickson G., Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Human Molecular Genetics 1995 4 8 1245 1250 2-s2.0-0029122522
39. Phelps S. F., Hauser M. A., Cole N. M., Rafael J. A., Hinkle R. T., Faulkner J. A., Chamberlain J. S., Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Human Molecular Genetics 1995 4 8 1251 1258 2-s2.0-0029122523
40. Neri M., Torelli S., Brown S., Ugo I., Sabatelli P., Merlini L., Spitali P., Rimessi P., Gualandi F., Sewry C., Ferlini A., Muntoni F., Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscular Disorders 2007 17 11-12 913 918 2-s2.0-36248985708 10.1016/j.nmd.2007.07.005 (Pubitemid 350137731)